Key result
Altered myocardial metabolism and insulin resistance contribute to heart failure pathogenesis, suggesting that metabolic modulators may serve as potential therapeutic options.
This review highlights the importance of understanding metabolic remodeling in heart failure and the potential therapeutic role of metabolic modulators.
Cautions against premature clinical use of metabolic modulators in HF; leaves open their efficacy pending randomized trials.
In addition to the typical abnormalities in myocardial structure and function, it is well established that the cardiac metabolism is abnormal in patients with heart failure (HF). Insulin resistance is a common co-morbidity in HF patients and also modulates cardiac metabolism in HF. The notion that an altered myocardial metabolism may contribute to the disease pathogenesis and optimizing it may serve therapeutic purposes underscores the importance of identifying the metabolic characteristics of HF patients. In this paper, the literature on the metabolic changes in human HF is reviewed, and the effects of metabolic modulators on patients with HF are discussed.
No takes yet. Share an insight, caveat, or question.
Tuunanen et al. (2011) conducted a review in Heart failure. Metabolic modulators was evaluated. Altered myocardial metabolism and insulin resistance contribute to heart failure pathogenesis, suggesting that metabolic modulators may serve as potential therapeutic options.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: